Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

PMCB RSS Feed
Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: bearspread, Top Penny, Hunchbackgeek, mind1, $Pistol Pete$, fraum
Search This Board: 
Last Post: 4/3/2020 12:24:06 AM - Followers: 825 - Board type: Free - Posts Today: 1

CEO sells block shares for .005

Let's look at KENNETH WAGGONER CEO OF PHARMACYTE attributes
 
A CEO of a penny stock

Was associated with 2 scam companies in the past.

Misleads investors with PR wording.

A lawyer, not a businessman and definitely not a Bio Tech person.

Has not been able to generate capital gains for Long term stockholders in PMCB since he joined the company in 2014.

Never has he purchased any shares in PMCB.

PMCB currently has 1.4 billion shares outstanding, without yet submitting an IND.

KW received over 1 million dollars in cash and stock and stock options in 2018, and the company not as yet have an approved product or filed an IND yet:

As Chief Executive Officer, President and General Counsel, Director at PHARMACYTE BIOTECH INC, Kenneth L. Waggoner made $1,004,360 in total compensation. Of this total $375,000 was received as a salary,$312,800 was received in stock options, $316,560 was awarded as stock. This information is according to proxy statements filed for the 2018 fiscal year.


 

Welcome to PharmaCyte BioTech

 

PharmaCyte Biotech “Release Testing” Successful on All Completed Tests of Clinical Trial ProductPress Release | 11/25/2019

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today an update on the completed tests that are part of the U.S. Food and Drug Administration (FDA) required “release testing” related to the company's first manufactured batch of its clinical trial product to be used in its planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

There are 10 total tests that make up the company’s “release testing.” To date, 5 of those 10 tests have been completed and all 5 have passed, including 4 of the 5 tests being conducted by third-party laboratories on the first manufactured batch of PharmaCyte’s clinical trial product.

PharmaCyte's partner, Austrianova Singapore (Austrianova), is conducting 5 of the tests, which are all related to the “functionality” of the encapsulated cells, while third-party laboratories are conducting the remaining 5 tests, which are all related to the “safety” of the company’s clinical trial product.

Among those successful tests was the “enzymatic activity” test that was performed by Austrianova. The last remaining test being conducted by a third-party laboratory is still in progress and is being conducted in the Netherlands by Eurofins.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said of the release testing, “We continue to be pleased that we've completed all of our manufacturing runs successfully and that we have a clinical trial product. Now, we follow that initial news with more good news that all of the release testing from the first successful manufacturing run carried out so far has been completed successfully.

“While the release testing is being conducted, we’re working to finalize the Protocol, the Investigator Brochure, the Pharmacy Manual and the Angiography Guidelines. We are also engaged in a selection process for a vendor to handle our clinical drug supply chain. All of these tasks should be complete by the time we receive the data from all of the release testing being conducted on the first and second manufacturing runs.

“After we receive all of the results from release testing, we will enter the data from those results into our Investigational New Drug application (IND) and then submit an entire package of information and supporting documents to the FDA for our planned Phase 2b clinical trial in LAPC.”

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is developing the use of genetically modified liver cells and stem cells, as well as beta islet cells, to treat diabetes. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte, including statements regarding the timing and commencement of our first Phase 2b clinical trial. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise

More information about PharmaCyte can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

https://cts.businesswire.com/ct/ct?id="bwnews&sty=20191125005256r1&sid=otc04&distro=ftp" "="" rel="nofollow" target="_blank">View source version on businesswire.com: https://www.businesswire.com/news/home/20191125005256/en/






PMCB SECURITY DETAILS

 

Market Cap
50,370,020
03/19/2020
Authorized Shares
2,490,000,000
10/29/2019
1,481,471,172
03/13/2020
Restricted
Not Available
 
Unrestricted
Not Available
 
Held at DTC
1,219,357,221
03/06/2020
Float
1,359,371,172
02/03/2020
Par Value
0.0001



 For more updated information please visit:  
http://www.otcmarkets.com/stock/PMCB/profile or more updated information please visit:

PMCB
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB News: Current Report Filing (8-k) 01/21/2020 05:15:58 PM
PMCB News: Quarterly Report (10-q) 12/23/2019 04:38:24 PM
PMCB News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 12/16/2019 06:10:41 AM
PMCB News: Current Report Filing (8-k) 11/08/2019 05:28:41 PM
PostSubject
#118746  Sticky Note PMCB's primary function since KW took over is fraum 03/17/20 03:17:39 PM
#115813  Sticky Note $PMCB CEO sells block shares for .005 $Pistol Pete$ 02/13/20 05:48:56 PM
#115802  Sticky Note $PMCB PharmaCyte Biotech: Smells Like A Pump And Dump $Pistol Pete$ 02/13/20 05:23:11 PM
#115747  Sticky Note KW rocks!!!! mind1 02/13/20 10:17:44 AM
#108244  Sticky Note A Smorgasbord of Q&A bearspread 12/01/19 01:31:42 PM
#120314   At least u can get your money back $Pistol Pete$ 04/03/20 12:24:06 AM
#120313   livendi, I haven't heard any response from IR regarding tjclark0551 04/02/20 11:21:56 PM
#120312   I hope so efood but sooner or later livendi 04/02/20 10:57:54 PM
#120311   Still waiting for more than words that pmcb efood125 04/02/20 10:42:47 PM
#120310   $PMCB well said “This company is a scam $Pistol Pete$ 04/02/20 10:02:08 PM
#120309   Lots of red flags here that are only livendi 04/02/20 08:15:53 PM
#120308   This is a man on a mission? IMO joe_techi 04/02/20 07:08:28 PM
#120307   you are 100% correct edwardport 04/02/20 06:36:19 PM
#120306   you are sleeping my friend edwardport 04/02/20 06:35:26 PM
#120305   Uncle Kenny thanks you. He needs you to Redoocs 04/02/20 05:58:20 PM
#120304   since kenny is using the virus as an thenewmixer 04/02/20 05:53:02 PM
#120303   LOL good choice thenewmixer 04/02/20 05:45:02 PM
#120302   Look in the Mirror. concordia 04/02/20 05:02:32 PM
#120301   LOL its not like they are profiting any joe_techi 04/02/20 04:56:08 PM
#120299   nobody here, except the kk group, knows whats tulla236a 04/02/20 04:35:32 PM
#120298   until kw and the mysterious bod give us tulla236a 04/02/20 04:29:28 PM
#120297   Nobody wants to see Uncle Kenny reap anymore Redoocs 04/02/20 04:16:29 PM
#120295   PMCB RED LOL April 15th all over again thenewmixer 04/02/20 03:59:56 PM
#120289   Nope it is not and it is more $Pistol Pete$ 04/02/20 03:38:16 PM
#120288   $PMCB completely scam with dilution from $.62 to $.02 $Pistol Pete$ 04/02/20 03:37:48 PM
#120284   So there is no proof of a scam bearspread 04/02/20 03:31:08 PM
#120283   Maybe Facet is trying to figure out what Redoocs 04/02/20 03:28:49 PM
#120281   Well said! fnyack 04/02/20 03:23:44 PM
#120280   Really.....I saw it red $Pistol Pete$ 04/02/20 03:23:04 PM
#120278   So there is no proof of a scam efood125 04/02/20 03:02:59 PM
#120275   First positive news I have heard in a ambitious1 04/02/20 01:51:16 PM
#120274   Never mind. You do you. Best of luck Fordman65 04/02/20 01:50:38 PM
#120273   nice day here lol pmcb green longboarder7892 04/02/20 01:41:14 PM
#120272   RC....there is no other start up with this bearspread 04/02/20 01:29:43 PM
#120270   never on PMCB......I play Kennys game..........watch when the thenewmixer 04/02/20 01:17:27 PM
#120269   So you have NEVER lost? Absurd! rcstock 04/02/20 01:14:44 PM
#120268   I take 10% every time from longs who thenewmixer 04/02/20 01:08:46 PM
#120267   You wouldn't take a 60% gain?? wow rcstock 04/02/20 01:06:37 PM
#120266   thenewmixer 04/02/20 12:58:28 PM
#120265   back up to 5 cents LOL thenewmixer 04/02/20 12:54:44 PM
#120264   but guess what? this type of thievery is bearspread 04/02/20 12:46:22 PM
#120263   People, everyone must understand: THIS IS A PENNY rcstock 04/02/20 12:26:38 PM
#120261   It’s shameful what they’re doing, but guess what? fnyack 04/02/20 12:26:04 PM
#120258   This company is a scam and the public Otsy 04/02/20 12:23:58 PM
#120257   IND not even submit and how are we $Pistol Pete$ 04/02/20 12:12:34 PM
#120256   so you guarantee pmcb will make people money? thenewmixer 04/02/20 11:58:14 AM
#120255   RC....there is no other start up with this efood125 04/02/20 11:55:54 AM
#120254   Only if you want to fund Uncle Kenny's Redoocs 04/02/20 11:50:34 AM
#120253   Best penny stock buy. Huge gain potential rcstock 04/02/20 11:40:26 AM
#120251   what year thenewmixer 04/02/20 11:01:57 AM
#120249   link to CT thenewmixer 04/02/20 10:49:00 AM
#120245   game changer treatment for all solid tumors rcstock 04/02/20 10:00:53 AM
#120244   i think i came up with kw next excuse. tulla236a 04/02/20 10:00:22 AM
#120243   $PMCB June-July of 2030? Or 2090? This is a $Pistol Pete$ 04/02/20 09:59:25 AM
#120242   $$PMCB CEO sells block shares for .005 Let's $Pistol Pete$ 04/02/20 09:57:38 AM
PostSubject